Management of Metastatic Breast Cancer, Including SABCS Updates
The decision-making process for metastatic breast cancer should involve a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies.
Biomarker Assays for Treatment Selection of Advanced Breast Cancer

Biomarkers identify patients who are likely to respond to a given therapy. These assays and their interpretation can present challenges for clinicians.

Management of Rare Breast Cancers

The management of rare breast cancer subtypes represents a challenge in clinical practice.

Principles of Breast Reconstruction after Surgery

All women undergoing breast cancer treatment should be educated about breast reconstructive options as adapted to their individual clinical situation and be offered an opportunity to consult with a reconstructive plastic surgeon. Coordinating consultation and surgical treatment with a reconstruct

Is There a Role for Proton Therapy in the Treatment of Breast Cancer?

Locoregional management strategies have considerably evolved.  Considerable progress has been made in understanding which patients will benefit from radiation therapy and ways to administer treatment that maximize clinical benefit while minimizing toxicity; however, many controversies exist as we

Surgical Management of Breast Cancer, Including SABCS Updates

Locoregional management strategies have considerably evolved.

Adjuvant and Neoadjuvant Therapies for Early Stage Breast Cancer, Including SABCS Updates
Clinicians are challenged to stay up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy so they can provide appropriate care using a shared decision making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.
Genetics/Familial Risk Assessment for Breast Cancer: Controversies and Evolving Principles

There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.

NCCN 2020 Congress Series™: Breast Cancer with Updates from 2019 San Antonio Breast Cancer Symposium

Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.

Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of HER-2 Positive Breast Cancer
It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.

Pages

Subscribe to RSS - Breast Cancer